Trials / Not Yet Recruiting
Not Yet RecruitingNCT06516484
Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of roprostin in the treatment of refractory AA after radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim | Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months. |
Timeline
- Start date
- 2024-07-30
- Primary completion
- 2025-07-31
- Completion
- 2025-12-31
- First posted
- 2024-07-24
- Last updated
- 2024-07-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06516484. Inclusion in this directory is not an endorsement.